Drug
Sb773812
Sb773812: highest development phase Phase 1, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| SB773812 NCT00197093 | Phase 1 | Schizophrenia |
Latest
No recent events.
Follow Sb773812 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.